484 related articles for article (PubMed ID: 25621812)
1. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
2. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).
Schuller E; Klingler A; Dubischar-Kastner K; Dewasthaly S; Müller Z
Vaccine; 2011 Nov; 29(47):8669-76. PubMed ID: 21907747
[TBL] [Abstract][Full Text] [Related]
4. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
5. IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis.
Jelinek T
Expert Rev Vaccines; 2013 Aug; 12(8):859-69. PubMed ID: 23984958
[TBL] [Abstract][Full Text] [Related]
6. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.
Dubischar-Kastner K; Kaltenboeck A; Klingler A; Jilma B; Schuller E
Vaccine; 2010 Sep; 28(39):6463-9. PubMed ID: 20673824
[TBL] [Abstract][Full Text] [Related]
7. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
8. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO
Amicizia D; Zangrillo F; Lai PL; Iovine M; Panatto D
J Prev Med Hyg; 2018 Mar; 59(1):E99-E107. PubMed ID: 29938245
[TBL] [Abstract][Full Text] [Related]
9. Ixiaro: a new vaccine against Japanese encephalitis.
Jelinek T
Expert Rev Vaccines; 2009 Nov; 8(11):1501-11. PubMed ID: 19863241
[TBL] [Abstract][Full Text] [Related]
10. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
[TBL] [Abstract][Full Text] [Related]
11. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.
Wang SY; Cheng XH; Li JX; Li XY; Zhu FC; Liu P
Hum Vaccin Immunother; 2015; 11(6):1418-25. PubMed ID: 25915588
[TBL] [Abstract][Full Text] [Related]
12. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
Rabe IB; Miller ER; Fischer M; Hills SL
Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
[TBL] [Abstract][Full Text] [Related]
13. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO
Jelinek T; Cromer MA; Cramer JP; Mills DJ; Lessans K; Gherardin AW; Barnett ED; Hagmann SHF; Askling HH; Kiermayr S; Kadlecek V; Eder-Lingelbach S; Taucher C; Dubischar KL
Travel Med Infect Dis; 2018; 22():18-24. PubMed ID: 29549036
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Dubischar KL; Kadlecek V; Sablan JB; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Kiermayr S; Spruth M; Westritschnig K
Pediatr Infect Dis J; 2017 Sep; 36(9):898-904. PubMed ID: 28430748
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
18. New Japanese encephalitis vaccines: alternatives to production in mouse brain.
Halstead SB; Thomas SJ
Expert Rev Vaccines; 2011 Mar; 10(3):355-64. PubMed ID: 21434803
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]